GM Statement

RNS Number : 4000D

Cizzle Biotechnology Holdings PLC

29 June 2021

 

29 June 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

GM Statement

Cizzle Biotechnology, the UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting ("GM") of the Company being held later today, Allan Syms, Executive Chairman, will make the following statement:

"Since the admission to trading of Cizzle Biotechnology on the London Stock Exchange in May I am pleased to report that we have already made significant progress with the development of our prototype CIZ1B biomarker test for the early detection of lung cancer, in line with the strategy outlined in the prospectus published in conjunction with admission.

"In addition to the work currently being undertaken at the University of York, we have now selected manufacturers and contract research organisations ("CROs") to conduct the required reagent generation, test manufacture and clinical validation to achieve CE marking and/or FDA 510(k) clearance for the test.  I am pleased to say that we are working with CROs that have proven track records of delivering robust and reliable reagents (together with monoclonal antibodies) for existing global pharmaceutical industry clients and I am confident that we will enter into definitive formal contractual arrangements with them as required.

"I am also pleased to report that we have commenced a robust health economics exercise to establish that the test satisfies the specific economic requirements and benefits required by the NHS and its patients.  We are also investigating additional global strategic alliances in order to facilitate the future commercial acceptance and roll-out of the test worldwide."

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	[phone]
John Depasquale
Alex Brearley

Novum Securities Limited	[phone]
Colin Rowbury Jon Bellis

IFC Advisory Limited	[phone]
Tim Metcalfe
Florence Chandler

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

END

 

 

GMSDKFBKBBKBQAB